SCHEMBL3384252

SCHEMBL3384252

Cc1[nH]c2ccccc2c1CCNC(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.69
MAPT P10636 7/20 0.59
PABPC1 P11940 1/20 0.59
ALOX15 P16050 1/20 0.59
TDP1 Q9NUW8 1/20 0.56
SNCA P37840 1/20 0.53
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
MAPK1 P28482 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3235845 0.87 ATM (0.66) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3230209 0.84 ATM (0.69) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL7863760 0.84 MAPT (0.72) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3384793 0.84 ATM (0.69) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3384593 0.83 ATM (0.67) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3384796 0.82 PABPC1 (0.62) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3384743 0.82 MAPT (0.67) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3230797 0.82 ATM (0.66) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3605297 0.81 ATM (0.65) ATMMAPTPABPC1ALOX15TDP1
SCHEMBL3385026 0.81 ATM (0.65) ATMMAPTPABPC1ALOX15TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor BAYER SCHERING PHARMA AG (DE) 2010-02-04 US claimed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP claimed
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor BAYER SCHERING PHARMA AG (DE) 2010-02-04 US disclosed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029598-A1 Extended Benzamide Derivatives as Modulators of the EP2 Receptor PTGER2, PTGER1, PTGDR2 ATM 4060/4885MAPT 4374/4885PABPC1 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.